CION Ameerpet
After Treatment · Reviewed by CION Oncologists · NABH Accredited
Endometrial Cancer Recurrence — Risk, Signs and Monitoring
The fear of it coming back is, for most women, harder than the treatment was. So the useful things first. Most endometrial cancer treated at an early stage does not recur. Where it does, it happens most often within the first three years, and most often at the top of the vagina — which is also the site where it is most treatable, sometimes still with the aim of cure. And the way it is usually found is not a scan. It is a symptom a woman notices and reports, or something seen at a routine examination. Knowing what to report is the most useful thing this page can give you.
- Most early disease does not come back — and the risk falls further with each year that passes
- The vaginal vault is the commonest site — and vault recurrence is often still treated to cure
- Symptoms find it, not scans — routine imaging in women without symptoms is not standard practice
- Bleeding is the signal to report — any new vaginal bleeding after treatment needs an appointment
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What to Report — and Not Wait to Report
Since symptoms are what find most recurrences, knowing which ones matter is not a small thing. None of the following means the cancer has returned. All of them mean an appointment rather than a wait-and-see.
- Any vaginal bleeding. After a hysterectomy there should be none. New bleeding or persistent blood-stained discharge is the single most important symptom on this list, precisely because vault recurrence is the commonest kind and the most treatable when found early.
- Pelvic or abdominal pain that persists. Not a passing ache, but pain that continues over weeks, or a new pressure or fullness that does not settle.
- New swelling in one leg. This can indicate a clot or lymphatic obstruction, and either warrants prompt assessment. See leg lymphoedema.
- A persistent cough, breathlessness, or unexplained weight loss. Less common, and the reason they are on the list is that distant recurrence in the lungs or abdomen presents this way rather than with pelvic symptoms.
- New bladder or bowel change that does not settle. Difficulty passing urine, blood in the urine or stool, or a persistent change in bowel habit. Often nothing to do with cancer, and still worth checking rather than assuming.
The rule is simple and worth holding on to: a new symptom that lasts more than two or three weeks deserves an appointment, not a wait until the next scheduled one. Nobody in an oncology clinic thinks you are wasting their time by coming in. The women who cause difficulty are the ones who wait.
Did You Know? Women are often unsettled to learn that follow-up after endometrial cancer involves few scans, and interpret it as being under-monitored. It is the opposite: it is what the evidence supports. Studies comparing intensive imaging surveillance with symptom-directed follow-up in endometrial cancer have not shown a survival advantage for routine scanning of women without symptoms, and the great majority of recurrences are picked up because a woman reported a symptom or because something was found on examination. Routine scans do, however, reliably produce incidental findings that lead to further tests and considerable anxiety. This is why guidelines recommend history and examination as the core of follow-up, with imaging directed by symptoms. Sources: ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma; NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms; TOTEM randomised trial of intensive versus minimalist follow-up in endometrial cancer.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Where It Comes Back, and What That Means
The site of recurrence matters more than the fact of it, because the three patterns carry quite different treatment options and outlooks.
| Site | What it is | What treatment aims for |
|---|---|---|
| Vaginal vault | At the top of the vagina, where the cervix used to be. The commonest site, and the reason follow-up includes examining it. | Often still cure — particularly in a woman who has not had radiation before, where salvage radiotherapy can be very effective. See vault recurrence. |
| Pelvis and lymph nodes | In the pelvic tissues or the nodes that drain the uterus, outside the vaginal vault itself. | Sometimes cure, depending on extent and on what treatment has already been given. Usually a combination of radiation and drug treatment. |
| Distant sites | The abdominal cavity, lungs, liver, bone or distant nodes. | Usually control rather than cure, with systemic treatment as the backbone. Molecular status matters a great deal here. |
Why vault recurrence gets so much attention: it is both the most likely and the most salvageable. That is the entire reason vault brachytherapy is offered after surgery to women at intermediate risk, and the reason using a vaginal dilator after radiation matters — a vagina that has narrowed shut cannot be examined, and the vault is exactly where the first sign would appear.
Had Treatment and Noticed Something New?
Bleeding, persistent pain, or a new swelling. Most turn out to be nothing. Getting it checked quickly is what matters.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Found Early, Recurrence Is Often Still Treatable
Which is why reporting a symptom quickly matters far more than any scan you could be having.
Understanding your own risk
What Actually Raises the Risk
Risk is not a single number and it is not the stage on its own. These are the factors your oncology team weighed when deciding what treatment you needed and how closely to follow you.
Stage at diagnosis
The strongest broad predictor. Disease confined to the uterus at surgery carries a substantially lower risk of recurrence than disease that had reached the cervical stroma, the ovaries or the lymph nodes. Within stage 1, depth of invasion into the muscle wall matters in its own right — invasion of half the wall or more is a recognised risk factor, and it is one of the main reasons a woman with apparently early disease is offered radiation after surgery. See FIGO staging.
Grade and histological type
Grade 3 tumours recur more often than grade 1, and the non-endometrioid types — serous, clear cell and carcinosarcoma — behave differently again. Those types carry a higher risk of recurrence within the abdomen rather than only at the vault, which is why treatment after surgery is considered for them even at early stage, and why follow-up is more attentive to abdominal symptoms. If your report names one of these, the stage number alone understates the situation. See Type 2 endometrial cancer.
Lymphovascular space invasion
Reported as LVSI, this means tumour cells were seen inside the small lymphatic and blood vessels in the uterine wall — evidence that the tumour had found a route to travel by. Substantial LVSI is an independent risk factor and raises the risk category even where the stage and grade look modest. It is one of the commonest reasons a woman is offered radiation when she expected to need nothing, and it is worth asking whether your report mentioned it.
Molecular group
Now built into FIGO staging and genuinely informative about recurrence risk. A p53-abnormal tumour carries a higher risk of recurrence and of distant spread regardless of how modest the stage appears, and is followed more closely. A POLE-mutated tumour behaves remarkably well even at high grade, and European guidance supports less treatment rather than more for this group. Mismatch repair deficiency has treatment implications if recurrence does occur, because it predicts response to immunotherapy. See MMR and MSI testing.
What treatment you had after surgery
Vault brachytherapy substantially reduces the risk of recurrence at the vaginal vault, which is why it is offered to the intermediate-risk group. Pelvic radiation reduces the risk of recurrence in the wider pelvis and nodes. Neither eliminates risk, and neither affects the risk of recurrence at distant sites, which is what systemic treatment addresses. Understanding which risk your treatment was aimed at helps make sense of what your follow-up is watching for. See the adjuvant decision.
How much time has passed
This is the factor women think about least and it works in their favour. The risk of recurrence is highest in the first two to three years after treatment and declines steadily thereafter. It is why follow-up appointments are frequent early and space out over time — the lengthening interval is a reflection of falling risk, not of reduced interest in you. Late recurrences do occur, particularly with low-grade hormone-sensitive tumours, which is why follow-up continues rather than stopping abruptly.
New Bleeding After Treatment?
That is the symptom worth acting on rather than waiting out. We will see you quickly and examine the vault properly. The opinion is free.
What Follow-Up Should Actually Involve
Follow-up appointments after endometrial cancer are shorter and simpler than most women expect, and that is deliberate rather than neglectful.
- A conversation about symptoms. This is the most productive part of the appointment, because symptoms are what find most recurrences. Come with anything you have noticed written down — it is easy to dismiss something in the moment.
- An examination, including the vaginal vault. A speculum examination to inspect the vault, and an internal examination of the pelvis. This is the part that finds vault recurrence before it causes symptoms, and it is the reason dilator use after radiation matters practically as well as sexually.
- Imaging only when there is a reason. Directed by a symptom or an abnormal examination, not performed routinely. Routine scanning of women without symptoms has not been shown to improve survival, and it reliably generates incidental findings and anxiety.
- Intervals that lengthen over time. Closer in the first two to three years when risk is highest, spacing out thereafter. See the follow-up schedule for how this is usually structured.
One thing follow-up should also cover, and often does not: the effects of the treatment you had. Menopausal symptoms, vaginal dryness, bowel or bladder changes, lymphoedema and fatigue are all legitimate things to raise at a follow-up appointment, and they are far more likely to be affecting you than a recurrence is. See life after endometrial cancer treatment.
Prognosis, Survival and Recurrence — Every Guide
The questions people ask after treatment ends, answered one at a time.
- Endometrial cancer survival by stage — what the numbers mean
- Vaginal vault recurrence — why brachytherapy matters
- Follow-up schedule after endometrial cancer treatment
- Prognosis for Type 2 (serous / clear cell) disease
- Living with advanced endometrial cancer
- What affects endometrial cancer prognosis
- How & where endometrial cancer spreads
- Is endometrial cancer a terminal illness?
What Good Follow-Up Looks Like
Fewer scans, better examinations, and someone who answers the phone when something changes.
Follow-up you can actually keep
Survivorship care that is actually offered
Vault brachytherapy on site
MMR / MSI testing as standard
Tumour board for every diagnosis
Psycho-oncology and nutrition on the team
Take The Next Step
Reporting It Early Is the Whole Point
Most new symptoms after treatment turn out to be nothing. Checking is quick, and it is exactly what follow-up is for.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Endometrial Cancer Recurrence — Frequently Asked Questions
How likely is endometrial cancer to come back?
For most women treated at an early stage, it does not. Endometrial cancer is usually found while still confined to the uterus, and treatment at that stage is frequently curative. Risk rises with stage, with grade, with depth of invasion into the muscle wall, with substantial lymphovascular invasion, with the non-endometrioid histological types, and with a p53-abnormal molecular group. It falls with time: recurrence is most likely in the first two to three years after treatment and becomes progressively less likely thereafter, which is why follow-up appointments start close together and space out. Your own risk is best discussed with the team that holds your pathology, because it depends on the combination rather than any single factor.
What are the signs that endometrial cancer has come back?
The most important one is vaginal bleeding. After a hysterectomy there should be none, so any new bleeding or persistent blood-stained discharge needs an appointment rather than a wait. Others worth reporting are pelvic or abdominal pain that persists over weeks, new swelling in one leg, a persistent cough or breathlessness, unexplained weight loss, and a bladder or bowel change that does not settle. None of these means the cancer has returned — most turn out to be something else entirely — but all of them warrant being checked. The practical rule is that a new symptom lasting more than two or three weeks deserves an appointment, not a wait until the next scheduled visit.
Why don't I have regular scans after treatment?
Because they have not been shown to help, and they do cause harm of their own. Studies comparing intensive imaging surveillance with symptom-directed follow-up in endometrial cancer have not demonstrated a survival advantage for routinely scanning women who have no symptoms. Meanwhile, routine scans reliably turn up incidental findings that lead to more tests, more waiting and considerable anxiety, and they involve radiation exposure. The great majority of recurrences are found because a woman reported a symptom or because something was seen at examination. That is why guidelines recommend history and clinical examination as the core of follow-up, with imaging arranged when there is a reason for it.
If it comes back, can it still be treated?
Yes, and in some situations still with the aim of cure — which is why finding it early matters so much. The commonest site of recurrence is the vaginal vault, and that is also the most salvageable: in a woman who has not previously had radiation, salvage radiotherapy to a vault recurrence can be highly effective and is given with curative intent. Recurrence in the pelvis or lymph nodes is sometimes still curable depending on extent and on what treatment has already been given. Recurrence at distant sites is usually treated to control rather than cure, and here molecular status matters greatly — mismatch repair deficient disease may respond well to immunotherapy.
Does using a vaginal dilator really matter for detecting recurrence?
Yes, and this is the reason for it that most often goes unmentioned. Radiation causes the vaginal tissue to lose elasticity as it heals, and without regular stretching the vagina can narrow and shorten considerably. Your follow-up appointments involve a speculum examination to inspect the vaginal vault, because that is where recurrence most often appears first and where it can be seen before it causes symptoms. A vagina that has narrowed cannot be examined properly, which means the single most useful part of your follow-up is lost. Comfortable intercourse is the reason usually given for dilator use; being examinable is arguably the more important one.
Medical disclaimer: This page describes recurrence after endometrial cancer treatment in general terms and is reviewed by a CION oncologist, following current NCCN and ESGO–ESTRO–ESP guidance. It is not advice about your own case, and your individual risk depends on pathology specific to you. If you have new vaginal bleeding after treatment for endometrial cancer, or any new symptom lasting more than two to three weeks, contact your oncology team rather than waiting for your next scheduled appointment.